Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases

NARecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

February 20, 2027

Study Completion Date

September 30, 2027

Conditions
Autoimmune Disease
Interventions
GENETIC

CD19 CART

"Dose group dosage unit (CAR+T cells/kg) Acceptable dose range Expected sample size (± 30%, CAR+T cells/kg)~1. 0.5 × 106 0.4 × 106\~0.6 × 106 3-6 cases~2. 1.0 × 106 0.7 × 106\~1.3 × 106 3-6 cases~3. 2.0 × 106 1.4 × 106\~2.6 × 106 3-6 cases Dose escalation rule The enrollment starts from dose group 1, and if no DLT occurs in the 3 subjects included, they will be transferred to the next dose group. If one of the three subjects in a certain dose group develops DLT, three additional subjects will be added to the group for cell infusion at the same dose. If there is ≥ 1 case of DLT in the 3 additional cases, it will be reduced to the previous dose group. If there are only 3 subjects in the previous dose group at this time, an additional 3 subjects need to be added for the trial; If there are already 6 subjects in the previous dose group, the trial ends and this dose is the maximum tolerated dose (MTD)."

Trial Locations (1)

100070

RECRUITING

Beijing Gobroad Brond Hospital, Beijing

All Listed Sponsors
lead

Beijing Boren Hospital

OTHER